
Opinion|Videos|June 28, 2024
Unmet Needs in Multiple Myeloma Ahead of ASCO 2024
Alfred L. Garfall, MD, opens a discussion underscoring the unmet needs in multiple myeloma.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- Coming into ASCO 2024, what did you consider to be the largest unmet needs in the treatment and management of multiple myeloma (MM)?
- What are the latest trends and innovations you have observed in the treatment and management of MM leading up to and coming out of ASCO 2024?
- How does relapsed/refractory MM (RRMM), particularly after multiple lines of therapy, affect the quality of life of patients and their families?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Cytokines Linked With Drug Resistance in Ovarian Cancer, but Underlying Mechanisms Remain Unclear
2
Mepolizumab Reduces Health Care Resource Utilization, Work Impairment in Severe Asthma
3
CHEST 2025 Highlights: Future of Respiratory Vaccines and the Impact of Federal Funding Cuts
4
Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies
5














































